Dupixent Lawsuits Attorneys

Dupixent (dupilumab) has become one of the most widely prescribed biologic drugs in the United States for eczema, asthma, and other chronic inflammatory conditions. For many patients, it has provided meaningful relief when other treatments failed.

But growing evidence and a rising number of lawsuits suggest that, for some patients, Dupixent may be linked to a serious and unexpected complication: cutaneous T-cell lymphoma (CTCL), a rare and aggressive form of blood cancer that can initially appear similar to eczema or other skin conditions.

What Is Dupixent?

Dupixent is a prescription biologic medication manufactured by Sanofi and Regeneron Pharmaceuticals. It works by targeting specific proteins in the immune system, IL-4 and IL-13, that play a key role in inflammatory conditions such as:

• Atopic dermatitis (eczema)
• Asthma
• Chronic sinusitis with nasal polyps
• Eosinophilic esophagitis
• Other immune-related disorders

Since receiving FDA approval in 2017, Dupixent has been prescribed to hundreds of thousands of patients and has become a multi-billion-dollar blockbuster drug.

For many patients, it helps control severe symptoms. But concerns have emerged about whether the drug may interfere with immune system function in a way that allows certain cancers to go undetected or progress.

Dupixent and Cutaneous T-Cell Lymphoma (CTCL)

Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects white blood cells called T cells. In its early stages, CTCL can closely resemble eczema, including:

• Red, scaly patches of skin
• Persistent itching
• Rash-like lesions that do not respond to standard treatment

This similarity can make diagnosis difficult, and in some cases, patients continue taking Dupixent while the underlying cancer progresses.

Recent medical literature, adverse event reports, and regulatory signals have raised concerns about a possible association between Dupixent use and CTCL diagnoses in certain patients.

What the Lawsuits Allege

Dupixent lawsuits allege that the manufacturers, Sanofi and Regeneron, failed to provide adequate warnings about a potential link between the drug and cutaneous T-cell lymphoma (CTCL).

Plaintiffs argue that prescribing physicians and patients were not given clear, timely, or prominent information about the possibility that Dupixent use could be associated with serious lymphatic cancers that may initially present as common skin conditions.

Downplaying or Delaying Safety Signals

These cases also assert that early safety signals, emerging from clinical data, post-market reports, and adverse event submissions, were not properly investigated or were minimized. Critics allege that, instead of taking a precautionary approach and escalating warnings, the manufacturers continued to promote Dupixent as safe for long-term use without adequately disclosing potential cancer-related risks.

Lack of Clear Guidance During Ongoing Treatment

Another key allegation is that patients and doctors were left without meaningful guidance when symptoms resembling CTCL began to appear during treatment. Because CTCL can closely mimic eczema, some patients allegedly remained on Dupixent for extended periods while their underlying condition progressed without proper diagnostic clarity or drug-related warnings prompting reassessment.

Failure to Update Warnings Despite Reported Cases

Plaintiffs further claim that as reports of CTCL diagnoses in Dupixent users accumulated, the manufacturers failed to meaningfully update labeling or provide stronger warnings. These allegations focus on whether regulatory obligations were met as real-world evidence began to suggest a potential association between Dupixent use and serious lymphatic disorders.

Taken together, these lawsuits center on a core product liability question: whether patients and physicians were given complete and accurate information about known or reasonably foreseeable risks so they could make fully informed treatment decisions.

Who May Be Eligible to File a Dupixent Lawsuit?

Individuals who used Dupixent for atopic dermatitis, asthma, chronic sinusitis, or another approved condition and were later diagnosed with cutaneous T-cell lymphoma or related conditions such as mycosis fungoides or Sézary syndrome may be eligible to bring a claim.

These cases often focus on the timing of drug exposure and diagnosis, as well as whether early symptoms were misattributed to existing skin conditions.

Delayed or Misdiagnosed Skin Symptoms

Many potential claims involve patients whose early CTCL symptoms were initially treated as worsening eczema or inflammatory skin disease. Because Dupixent is commonly prescribed for those same conditions, there are allegations that continued treatment may have delayed accurate diagnosis or further medical investigation. 

Cases Involving Severe or Advanced Disease Progression

Eligibility may also extend to individuals whose condition progressed significantly after continued Dupixent use, particularly where later-stage lymphoma required aggressive treatment such as chemotherapy, radiation, or systemic therapy. These cases often involve questions about whether earlier intervention could have changed the course of the disease.

Wrongful Death Claims

In the most serious cases, families may pursue a wrongful death claim if a loved one passed away following a CTCL diagnosis after using Dupixent. These claims focus on both the loss suffered by the family and the medical circumstances leading up to the diagnosis and treatment timeline.

Each case is highly fact-specific. Medical records, pathology reports, prescription history, and the timing of symptom onset all play a critical role in determining whether a viable claim exists and how strong that claim may be.

Why These Cases Matter

CTCL is often misdiagnosed in its early stages because it mimics common inflammatory skin conditions. That overlap raises serious concerns about delayed diagnosis and disease progression in patients treated with Dupixent.

As more cases are investigated, attorneys are examining whether earlier warnings or stronger safety guidance could have changed treatment decisions or led to earlier detection.

Filing a Dupixent Claim in New York

If you or a loved one developed cutaneous T-cell lymphoma or another serious T-cell malignancy after using Dupixent, you may have the right to bring a product liability claim. These cases are focused on whether the drug’s risks were adequately disclosed and whether earlier warnings or clearer guidance could have changed the course of diagnosis, treatment, or outcomes.

Dupixent litigation is still developing, but cases across the country are being reviewed as part of broader investigations into whether patients were exposed to preventable harm. In New York, individuals may pursue claims individually or as part of coordinated mass tort litigation, depending on how the cases evolve.

Compensation Available in a Dupixent Lawsuit

A successful claim may allow injured patients and families to recover compensation for a range of losses tied directly to diagnosis, treatment, and long-term impact. This can include medical expenses such as hospital care, specialist consultations, diagnostic testing, chemotherapy, radiation, and ongoing treatment costs.

Claims may also seek recovery for lost income when a patient is unable to work due to illness or treatment, as well as reduced future earning capacity in more severe cases. In addition, Dupixent lawsuits often include damages for pain and suffering, reflecting the physical and emotional toll of both the disease and its treatment.

In fatal cases, surviving family members may pursue wrongful death damages, which can include funeral and burial expenses, loss of financial support, and the loss of companionship and guidance of a loved one.

HKD  is actively reviewing potential Dupixent claims and helping individuals determine whether their medical history may support a legal case.

Tell Us What Happened